See more : Queen’s Gambit Growth Capital (GMBT) Income Statement Analysis – Financial Results
Complete financial analysis of Glenmark Life Sciences Limited (GLS.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Glenmark Life Sciences Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- AUTORIDERS INTERNATIONAL LTD. (AUTOINT.BO) Income Statement Analysis – Financial Results
- GCM Resources Plc (GCM.L) Income Statement Analysis – Financial Results
- Brangista Inc. (6176.T) Income Statement Analysis – Financial Results
- Powszechna Kasa Oszczednosci Bank Polski Spólka Akcyjna (PKO.WA) Income Statement Analysis – Financial Results
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (688505.SS) Income Statement Analysis – Financial Results
Glenmark Life Sciences Limited (GLS.NS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.glenmarklifesciences.com
About Glenmark Life Sciences Limited
Glenmark Life Sciences Limited develops, manufactures, and supplies non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers Olmesartan, Amiodarone, Telmisartan, Perindopril, Rosuvastatin, and Cilostazol for cardiovascular diseases; Oxcarbazepine, Zonisamide, Topiramate, Bupropion, Ropinirole, Riluzole, and Lacosamide for central nervous system diseases; Glimepiride, Teneligliptin, Vildagliptin, and Linagliptin for diabetes; and Etoricoxib and Lornoxicam for pain management. It also provides Atovaquone, Voriconazole, Mirabegron, Desloratadine, Esomeprazole Magnesium, Adapalene, and Fluconazole gastro-intestinal disorders, anti-infective, respiratory, anti-emetic, and other therapeutic areas. In addition, the company offers contract development and manufacturing services to a range of multinational pharmaceutical and specialty pharmaceutical companies. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was incorporated in 2011 and is based in Mumbai, India. Glenmark Life Sciences Limited is a subsidiary of Glenmark Pharmaceuticals Limited.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 22.83B | 21.61B | 21.23B | 18.85B | 15.37B | 14.05B | 2.48M |
| Cost of Revenue | 10.40B | 10.14B | 10.43B | 9.05B | 6.90B | 6.26B | 2.37M |
| Gross Profit | 12.43B | 11.47B | 10.80B | 9.80B | 8.47B | 7.79B | 110.00K |
| Gross Profit Ratio | 54.45% | 53.08% | 50.88% | 51.97% | 55.09% | 55.41% | 4.44% |
| Research & Development | 752.97M | 651.77M | 571.96M | 2.90M | 400.28M | 1.44M | 0.00 |
| General & Administrative | 2.59B | 91.50M | 80.86M | 74.24M | 71.45M | 92.43M | 0.00 |
| Selling & Marketing | 115.47M | 246.18M | 317.81M | 337.88M | 263.24M | 267.13M | 0.00 |
| SG&A | 2.70B | 337.68M | 398.67M | 412.12M | 334.69M | 359.56M | 240.00K |
| Other Expenses | 0.00 | 289.57M | 3.19M | 3.81M | 3.96M | 330.00K | 0.00 |
| Operating Expenses | 3.45B | 5.47B | 5.01B | 4.18B | 4.03B | 3.69B | 240.00K |
| Cost & Expenses | 13.85B | 15.61B | 15.44B | 13.23B | 10.93B | 9.96B | 2.61M |
| Interest Income | 120.21M | 157.66M | 67.81M | 4.30M | 3.55M | 4.38M | 0.00 |
| Interest Expense | 15.46M | 5.47M | 279.62M | 875.47M | 335.15M | 6.05M | 0.00 |
| Depreciation & Amortization | 534.52M | 420.94M | 378.77M | 333.94M | 293.68M | 192.62M | 140.00K |
| EBITDA | 6.86B | 6.71B | 6.31B | 5.92B | 4.84B | 2.48B | 10.00K |
| EBITDA Ratio | 30.06% | 31.06% | 29.74% | 31.43% | 31.56% | 30.64% | -5.24% |
| Operating Income | 8.98B | 6.01B | 5.79B | 5.62B | 4.44B | 2.36B | -130.00K |
| Operating Income Ratio | 39.33% | 27.80% | 27.27% | 29.80% | 28.87% | 16.78% | -5.24% |
| Total Other Income/Expenses | -2.67B | -2.31B | -2.59B | -2.84B | -2.05B | -54.36M | 0.00 |
| Income Before Tax | 6.31B | 6.29B | 5.65B | 4.71B | 4.21B | 4.04B | -130.00K |
| Income Before Tax Ratio | 27.65% | 29.09% | 26.61% | 24.98% | 27.39% | 28.74% | -5.24% |
| Income Tax Expense | 1.60B | 1.62B | 1.46B | 1.19B | 1.08B | 1.11B | 4.21M |
| Net Income | 4.71B | 4.67B | 4.19B | 3.52B | 3.13B | 2.93B | -4.34M |
| Net Income Ratio | 20.62% | 21.61% | 19.72% | 18.65% | 20.37% | 20.83% | -175.00% |
| EPS | 38.43 | 38.11 | 35.63 | 32.61 | 29.04 | 23.89 | -0.04 |
| EPS Diluted | 38.38 | 38.11 | 35.63 | 32.61 | 29.04 | 23.89 | -0.04 |
| Weighted Avg Shares Out | 122.53M | 122.53M | 117.53M | 107.80M | 107.80M | 122.53M | 107.80M |
| Weighted Avg Shares Out (Dil) | 122.69M | 122.53M | 117.53M | 107.80M | 107.80M | 122.53M | 107.80M |
Source: https://incomestatements.info
Category: Stock Reports